(15047922), G. J., (15047925), T. Y., (15047928), F. L., (15047931), J. C., (15047934), M. A. E., (15047937), M. M., . . . (15047946), C. H. (2025). Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas.
Chicago Style (17th ed.) Citation(15047922), Gerhard Jungwirth, et al. Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas. 2025.
MLA (9th ed.) Citation(15047922), Gerhard Jungwirth, et al. Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas. 2025.